Abstract
The dentate gyrus (DG) is one of only two brain structures known to retain the ability to produce new neurons in adulthood. The functional significance of adult neurogenesis in the DG is not yet well understood, but recent evidence has implicated adult neurogenesis in the etiology and treatment of depression. Elevated stress hormone levels, which are present in some depressed patients and can precipitate the onset of depression, reduce neurogenesis in animal models. Conversely, virtually all antidepressant treatments studied to date, including drugs of various classes, electroconvulsive therapy, and behavioral treatments, increase neurogenesis in the DG. We critically review this literature linking DG neurogenesis with depression, looking to both animal and human studies. We conclude that a reduction in neurogenesis by itself is not likely to produce depression. However, at least some therapeutic effects of antidepressant treatments appear to be neurogenesis-dependent. We review the cellular pathways through which antidepressant drugs boost neurogenesis and present several hypotheses about how DG neurogenesis may be instrumental in the therapeutic effects of these drugs.
Keywords: subgranular zone, long-term potentiation, Emotion, Stress, Hippocampal Atrophy
CNS & Neurological Disorders - Drug Targets
Title: Adult Hippocampal Neurogenesis as Target for the Treatment of Depression
Volume: 6 Issue: 3
Author(s): Michael R. Drew and Rene Hen
Affiliation:
Keywords: subgranular zone, long-term potentiation, Emotion, Stress, Hippocampal Atrophy
Abstract: The dentate gyrus (DG) is one of only two brain structures known to retain the ability to produce new neurons in adulthood. The functional significance of adult neurogenesis in the DG is not yet well understood, but recent evidence has implicated adult neurogenesis in the etiology and treatment of depression. Elevated stress hormone levels, which are present in some depressed patients and can precipitate the onset of depression, reduce neurogenesis in animal models. Conversely, virtually all antidepressant treatments studied to date, including drugs of various classes, electroconvulsive therapy, and behavioral treatments, increase neurogenesis in the DG. We critically review this literature linking DG neurogenesis with depression, looking to both animal and human studies. We conclude that a reduction in neurogenesis by itself is not likely to produce depression. However, at least some therapeutic effects of antidepressant treatments appear to be neurogenesis-dependent. We review the cellular pathways through which antidepressant drugs boost neurogenesis and present several hypotheses about how DG neurogenesis may be instrumental in the therapeutic effects of these drugs.
Export Options
About this article
Cite this article as:
Drew R. Michael and Hen Rene, Adult Hippocampal Neurogenesis as Target for the Treatment of Depression, CNS & Neurological Disorders - Drug Targets 2007; 6 (3) . https://dx.doi.org/10.2174/187152707780619353
DOI https://dx.doi.org/10.2174/187152707780619353 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preterm Birth and the Risk of Neurodevelopmental Disorders - Is There a Role for Epigenetic Dysregulation?
Current Genomics Medical Applications of Implantable Drug Delivery Microdevices Based on MEMS (Micro-Electro-Mechanical-Systems)
Current Pharmaceutical Biotechnology Anti-Carcinogenic Effects of Carnosol-An Updated Review
Current Drug Discovery Technologies Kv7 Channels: Function, Pharmacology and Channel Modulators
Current Topics in Medicinal Chemistry Non-canonical Molecular Targets for Novel Analgesics: Intracellular Calcium and HCN Channels
Current Neuropharmacology Advances in the Physiology of GPR55 in the Central Nervous System
Current Neuropharmacology Incorporating Natural Products, Pharmaceutical Drugs, Self-Care and Digital/Mobile Health Technologies into Molecular-Behavioral Combination Therapies for Chronic Diseases
Current Clinical Pharmacology Pediatric Epilepsy Surgery: Neuropsychological and Psychosocial Outcomes
Current Pediatric Reviews Herbal Compounds with Special Reference to Gastrodin as Potential Therapeutic Agents for Microglia Mediated Neuroinflammation
Current Medicinal Chemistry Structure-Affinity-Relationship Study of Bicyclic σ Receptor Ligands
Central Nervous System Agents in Medicinal Chemistry Thymoquinone: Major Molecular Targets, Prominent Pharmacological Actions and Drug Delivery Concerns
Current Bioactive Compounds Barbiturates: A Review of Synthesis and Antimicrobial Research Progress
Current Organic Synthesis Editorial (Thematic Issue: Neurology and Genetics: How Molecular Biology is Changing the Neurological Thoughts?)
Current Molecular Medicine Disorders of Consciousness and Electrophysiological Treatment Strategies: A Review of the Literature and New Perspectives
Current Pharmaceutical Design Congenital Cytomegalovirus Prevention, Awareness and Policy Recommendations - A Scoping Study
Infectious Disorders - Drug Targets Relevance of Excitable Media Theory and Retinal Spreading Depression Experiments in Preclinical Pharmacological Research
Current Neuropharmacology Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Current Pharmaceutical Design Bipolar Spectrum Disorder: Origins and State of the Art
Current Psychiatry Reviews Vascular and Parenchymal Mechanisms in Multiple Drug Resistance: a Lesson from Human Epilepsy
Current Drug Targets The Animal Models of Dementia and Alzheimer’s Disease for Pre-Clinical Testing and Clinical Translation
Current Alzheimer Research